Innoviva opened higher at $18.99, compared with its previous close of $18.86. In the last trading session, the stock traded between $18.86 and $19.24. It showed a sideways intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Innoviva is now worth
$ 106.48
Giving a profit of
$ 6.48 (6.48%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 2 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
+$0.12 (+0.61%)
Day High
$19.24
Day Low
$18.86
Day Open
$18.99
Prev Close
$18.86
Volume
4,38,607
1W Return
-10.69%
1M Return
-11.56%
3M Return
-8.45%
6M Return
-15.74%
1Y Return
-13.36%
Fundamentals
Market Cap ($ Mn)
1,349
PE Ratio
4.90
PB Ratio
1.24
PEG Ratio
0.42
ROE
32.01%
ROCE
26.27%
EPS (TTM)
$-1.03
Investment Returns
1 Week
-10.69%
1 Month
-11.56%
3 Months
-8.45%
6 Months
-15.74%
9 Months
-15.59%
Financials
Quarterly
All values in $ Mn
100.3
Jun 25
107.8
Sep 25
114.6
Dec 25
98.0
Mar 26
119.6
Jun 26
106.1
Sep 26
Updates
6Nov
Oppenheimer lowers Innoviva price target to $34, keeps outperform
Oppenheimer lowered Innoviva's price target to $34 from $35. Analyst Les Sulewski maintained an Outperform rating on the stock.
7 days ago
12Aug
Innoviva names three antimicrobial therapies as Prix Galien finalists
Innoviva Specialty Therapeutics has secured finalist status for three key antimicrobial therapies—XACDURO, ZEVTERA, and NUZOLVENCE—in the 2026 Prix Galien USA Awards. This achievement marks the third consecutive year of recognition for the company, highlighting its portfolio's scientific merit in treating drug-resistant infections. Winners will be announced on October 29, 2026.
3mo ago
6Aug
Innoviva Q2 Results: EPS Misses Estimate as Sales Beat
Innoviva’s Q2 results show a mixed bag: while sales of $119.600M beat estimates and rose 19.26% YoY, EPS plunged to a loss of $1.14, missing the $0.40 estimate by 385%. This signals significant margin pressure despite strong demand.
3mo ago
16Jun
Innoviva, Dr. Reddy's partner to commercialize XACDURO
Innoviva Specialty Therapeutics and Dr. Reddy's Laboratories have partnered to develop and commercialize XACDURO in South and Central America, the Caribbean, Russia, and CIS. XACDURO is approved in the US for treating HABP/VABP caused by Acinetobacter.
